Mohamed Hamza1, Ahmed Mahmoud2, Islam Y Elgendy3. 1. Department of Cardiology, Ain-Shams University, Cairo, Egypt. 2. Division of Cardiology, Department of Medicine, University of Florida, Gainesville, Florida. 3. Department of Medicine, University of Florida, Gainesville, Florida.
Abstract
BACKGROUND: Recent randomized trials and meta-analyses demonstrated that a complete revascularization of significant non culprit lesions in patients with ST elevation myocardial infarction (STEMI) is superior to a culprit only revascularization approach in reducing major adverse cardiac events (MACE), however the proportion of diabetic patients was low in these trials. OBJECTIVES: To investigate whether a complete revascularization approach is associated with better outcomes in diabetic patients with STEMI and multi-vessel disease. METHODS:One hundred diabetic patients with acute STEMI with at least one non-culprit lesion were randomized to either complete revascularization (n = 50) or culprit-only treatment (n = 50). Complete revascularization was performed either at the time of primary percutaneous coronary intervention (PCI) or within 72 hours during hospitalization. The primary endpoint was the composite of all-cause mortality, recurrent MI, and ischemia-driven revascularization at 6 months. RESULTS: A complete revascularization approach was significantly associated with a reduction in the primary outcome (6% vs. 24%, P = 0.01), primarily due to reduction in ischemia driven revascularization in the complete revascularization group (2% vs. 12%; P = 0.047). There was no significant reduction in death or MI (2% vs. 8%; P = 0.17) and (2% vs. 4%; P = 0.56) respectively, or in the safety endpoints of major or minor bleeding, contrast-induced nephropathy, or stroke between the groups. CONCLUSIONS: In diabetic patients with multi-vessel coronary artery disease undergoing PPCI, complete revascularization is associated with significantly reduced risk of adverse cardiovascular events, as compared with culprit vessel only PCI. (J Interven Cardiol 2016;29:241-247).
RCT Entities:
BACKGROUND: Recent randomized trials and meta-analyses demonstrated that a complete revascularization of significant non culprit lesions in patients with ST elevation myocardial infarction (STEMI) is superior to a culprit only revascularization approach in reducing major adverse cardiac events (MACE), however the proportion of diabeticpatients was low in these trials. OBJECTIVES: To investigate whether a complete revascularization approach is associated with better outcomes in diabeticpatients with STEMI and multi-vessel disease. METHODS: One hundred diabeticpatients with acute STEMI with at least one non-culprit lesion were randomized to either complete revascularization (n = 50) or culprit-only treatment (n = 50). Complete revascularization was performed either at the time of primary percutaneous coronary intervention (PCI) or within 72 hours during hospitalization. The primary endpoint was the composite of all-cause mortality, recurrent MI, and ischemia-driven revascularization at 6 months. RESULTS: A complete revascularization approach was significantly associated with a reduction in the primary outcome (6% vs. 24%, P = 0.01), primarily due to reduction in ischemia driven revascularization in the complete revascularization group (2% vs. 12%; P = 0.047). There was no significant reduction in death or MI (2% vs. 8%; P = 0.17) and (2% vs. 4%; P = 0.56) respectively, or in the safety endpoints of major or minor bleeding, contrast-induced nephropathy, or stroke between the groups. CONCLUSIONS: In diabeticpatients with multi-vessel coronary artery disease undergoing PPCI, complete revascularization is associated with significantly reduced risk of adverse cardiovascular events, as compared with culprit vessel only PCI. (J Interven Cardiol 2016;29:241-247).
Authors: Claudio A Bravo; Sameer A Hirji; Deepak L Bhatt; Rachna Kataria; David P Faxon; E Magnus Ohman; Kevin L Anderson; Akil I Sidi; Michael H Sketch; Stuart W Zarich; Asishana A Osho; Christian Gluud; Henning Kelbæk; Thomas Engstrøm; Dan Eik Høfsten; James M Brennan Journal: Cochrane Database Syst Rev Date: 2017-05-03
Authors: Gani Bajraktari; Ibadete Bytyçi; Michael Y Henein; Fernando Alfonso; Ali Ahmed; Haki Jashari; Deepak L Bhatt Journal: Int J Cardiol Heart Vasc Date: 2020-06-13
Authors: Yousif Ahmad; James P Howard; Ahran Arnold; Megha Prasad; Henry Seligman; Christopher M Cook; Takayuki Warisawa; Matthew Shun-Shun; Ziad Ali; Manish A Parikh; Rasha Al-Lamee; Sayan Sen; Darrel Francis; Jeffrey W Moses; Martin B Leon; Gregg W Stone; Dimitri Karmpaliotis Journal: J Am Heart Assoc Date: 2020-06-01 Impact factor: 5.501
Authors: Roberto C Cerrud-Rodriguez; Syed Muhammad Ibrahim Rashid; Karlo A Wiley; Maday Gonzalez; Valeriia A Kosmacheva; Isabella Castillero-Norato; Cornelia Rivera; Pedro Villablanca; Jose Wiley Journal: Int J Gen Med Date: 2021-06-03